Provectus Pharmaceuticals, Inc. (PVCT.OB) Brings in $7.5M in a Private Placement
Provectus Pharmaceuticals, Inc., a developer of oncology and dermatology treatments, today announced gross proceeds of approximately $7.5M from a private placement. With intentions to apply the capital generated by this private placement to working capital concerns, PVCT CFO and COO Peter Culpepper noted that the closing of this offer has tremendously strengthened the Company’s operational activities and widely expanded PVCT’s base of shareholders “to include new and individual investors”. Culpepper went on to say that sufficient capital had been raised to fully finance ongoing clinical trials, and that no additional money would be required to complete testing on the Company’s…